NIAGEN BIOSCIENCE INC (NAGE)
Consumer Staples · NAD+ precursors and healthy aging supplements · NASDAQ
A global bioscience company commercializing nicotinamide riboside (Niagen®), a NAD+ precursor, through consumer supplements, pharmaceutical-grade ingredient supply, and clinical research collaborations targeting healthy aging.
What NIAGEN BIOSCIENCE INC does
Niagen Bioscience is a global bioscience company dedicated to promoting healthy aging through research, development, and commercialization of NAD+ precursors, primarily nicotinamide riboside chloride (NRC). The company operates across three business segments: (1) consumer products including Tru Niagen® dietary supplements and topical skincare products sold directly to consumers and through distributors; (2) ingredient supply of food-grade and pharmaceutical-grade Niagen® to manufacturers, 503B outsourcing facilities, and compounding pharmacies; and (3) pharmaceutical development with clinical research collaborations and Niagen Plus pharmaceutical-grade products for intravenous and injectable formulations. The company has established over 300 research collaborations with leading universities and research institutions to advance NAD+ science.
Themes: ["NAD+ biology and healthy aging","Dietary supplements","Pharmaceutical ingredients and compounding","Cellular metabolism and longevity","Consumer wellness products","Clinical research and medical foods"]
Fundamentals
- Price$3.49 as of 2026-07-09 close
- Market cap$274M as of 2026-07-10
- 1-year return-71.2% as of 2026-07-09 close
- P/E14.68 as of 2026-07-10
- Net margin+14.3% as of 2026-07-10
- Gross margin+64.3% as of 2026-07-10
- ROE+25.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+20.8% as of 2026-07-10
- Revenue CAGR (3y)+21.6% SEC XBRL
- Beta2.12 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Elysium Health (private, produces NAD+ precursor basis point)
- Apeiron Therapeutics (NAD+ biologics)
- Replicel Life Sciences (cellular aging)
- Calico Labs (longevity research)
- GlycoMimetics (rare disease therapeutics)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.